NAMS vs ZLAB: stock comparison and AI forecast
Newamsterdam Pharma Co N.V. (NAMS) and Zai Lab Ltd (ZLAB) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
NAMS Newamsterdam Pharma Co N.V.
- Market Cap
- $2.26B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
ZLAB Zai Lab Ltd
- Price
- $22.60 +7.6% · 6M
- Market Cap
- $2.57B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- ZLAB is 1.1 times larger than NAMS by market capitalization ($2.57B against $2.26B).
- ZLAB carries 0.82 times debt per unit of equity, against 0.09 times for NAMS.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | NAMS | ZLAB |
|---|---|---|
| Market Cap | $2.26B | $2.57B |
| P/B Ratio | 3.58x | 4.56x |
| EPS | $-1.25 | $-0.17 |
| Book Value/Share | $5.28 | $4.96 |
| Revenue/Share | $0.19 | $3.89 |
| FCF/Share | $-1.26 | $-1.44 |
Profitability & Margins
| Metric | NAMS | ZLAB |
|---|---|---|
| ROE | -32.5% | – |
| ROA | -29.8% | – |
| ROIC | -37.0% | -46.4% |
| Gross Margin | – | 54.7% |
| Operating Margin | -1052.8% | -63.0% |
| Net Margin | -924.0% | – |
| EBT Margin | -918.6% | -45.9% |
| Tax Rate | – | 2.2% |
Financial Health
| Metric | NAMS | ZLAB |
|---|---|---|
| Current Ratio | 11.76x | 2.04x |
| Quick Ratio | – | 1.84x |
| D/E Ratio | 0.09x | 0.82x |
| Financial Leverage | 1.09x | 1.82x |
| Interest Coverage | – | -42.7x |
| Working Capital | $615M | $440M |
Cash Flow
| Metric | NAMS | ZLAB |
|---|---|---|
| Operating Cash Flow | -$150M | -$159M |
| Free Cash Flow | -$151M | -$163M |
| Capital Spending | -$400K | -$4M |
| FCF/Sales | -680.4% | -37.0% |
| CapEx/Sales | 1.8% | 0.9% |
Operational Efficiency
| Metric | NAMS | ZLAB |
|---|---|---|
| Asset Turnover | 0.03x | 0.43x |
| Receivables Turnover | – | 6.8x |
| Inventory Turnover | – | 2.4x |
| Fixed Assets Turnover | 40.0x | 9.6x |
| Days Sales Outstanding | – | 54 days |
| Days Inventory | – | 156 days |
| Payables Period | – | 219 days |
| Cash Conversion Cycle | – | -10 days |
Income Statement
| Metric | NAMS | ZLAB |
|---|---|---|
| Total Revenue | $22M | $442M |
| Operating Income | -$233M | -$278M |
| Net Income | -$205M | – |
| R&D Expense | $158M | $239M |
| SG&A Expense | $102M | $281M |
| Cost of Goods Sold | – | $200M |
Dividend & Shareholder Information
| Metric | NAMS | ZLAB |
|---|---|---|
| Shares Outstanding | 120M | 114M |
NAMS vs ZLAB: stock comparison and AI forecast
Which is bigger, NAMS or ZLAB?
ZLAB is 1.1 times larger than NAMS by market capitalization ($2.57B against $2.26B).
Which one does Intratio's AI model rank higher, NAMS or ZLAB?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.